AzTrials
AzTrials

Advanced Malignant TumoursPhase 1NCT06929195

Clinical Trial to Evaluate the Tolerance of TQB2210 Injection

A Phase 1 study testing TQB2210 Injection in people with Advanced Malignant Tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. at 7 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Advanced Malignant Tumours
What is being tested?
TQB2210 Injection
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
7 sitesChina
Study dates
16 May 2025to 10 Apr 2026
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG-PS), score: 0-1; The expected survival time is more than 3 months.
  • At least one tumour lesion that can be evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 in the dose-escalation phase and at least one measurable lesion in the dose-expansion phase.
  • Good function of major organs.
  • Patients with advanced malignant tumours confirmed by histology or cytology, disease progression or intolerance after adequate standard treatment, lack of standard treatment options.
  • Can provide tumor tissue specimens collected fresh or sliced within 6 months (preserved in wax blocks collected within 3 years) for further detection for FGFR2b expression
  • Fertile subjects should agree that contraception must be used during the study and for 6 months after the end of the study; Women of childbearing age had a negative serum pregnancy test within 7 days prior to study enrollment and had to be non-lactating subjects.
  • Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.

Who cannot join

  • Has had or is currently suffering from other malignant tumors
  • There are diseases that affect intravenous injection and venous blood collection
  • Adverse reactions from previous treatments have not recovered to CTCAE v5.0 Grade 1
  • Received major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose of TQB2210, or exist long-term unhealed wounds or fractures
  • Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first dose of TQB2210
  • An arterial/venous thrombotic event occurred within 6 months prior to to the first dose of TQB2210
Show all 36Show fewer
  • Patients with active viral hepatitis that is poorly controlled
  • Active syphilis patients requiring treatment
  • A history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonitis/radiation pneumonia requiring treatment or active pneumonia with obvious clinical symptoms, interstitial pneumonia requiring treatment
  • Subjects with any severe and/or uncontrolled illnesses
  • Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation
  • History of hepatic encephalopathy
  • Suffering from significant cardiovascular disease
  • Active or uncontrolled severe infections
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Corneal defects, corneal ulcers, keratitis or keratoconus, history of corneal transplantation, or other known corneal abnormalities that may increase the risk of developing corneal ulcers within 6 months prior to the first treatment or currently present
  • History of retinal disease or retinal detachment, or increased risk of retinal detachment according to the opinion of an ophthalmologist
  • Acute ophthalmic diseases that continue to progress within the first 4 weeks of enrollment
  • Unwilling to avoid using contact lenses during research treatment
  • History of immunodeficiency, includingHuman Immunodeficiency Virus（HIV） positivity or other acquired or congenital immunodeficiency diseases
  • There are poorly controlled autoimmune diseases that require the use of immunosuppressants or systemic hormone therapy to achieve immunity Subjects who inhibit the purpose and need to continue using it within 7 days before the first administration
  • Individuals with epilepsy who require treatment
  • Poor control of diabetes
  • Tumor related symptoms and treatment:
  • Received chemotherapy, immunotherapy, small molecule targeted drugs, etc. within 3 weeks before the first administration;
  • Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA )approved drug directions within 1 week before the first drug use;
  • Imaging (Computed Tomography or Magnetic Resonance Imaging) shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
  • Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites that still require repeated drainage;
  • Known to have spinal cord compression, meningeal metastasis/malignant meningitis, accompanied by symptoms of brain metastasis, or symptoms/imaging control time less than 4 weeks. Within 2 weeks before the start of treatment, steroid therapy or dehydration agents are still required;
  • For non-small cell lung cancer subjects known to have meaningful gene mutations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion, ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS) fusion, etc., they should have received corresponding targeted therapy;
  • Subjects with known human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction cancer and breast cancer should have received corresponding anti HER2 treatment;
  • Known to be allergic to research drug excipient components
  • Previously received targeted FGFR2b monoclonal antibod therapy
  • Previously received chemotherapy drugs used in the protocol (limited to subjects receiving combination therapy during the dose escalation phase only)
  • Individuals who have participated in and used other anti-tumor clinical trial drugs within 4 weeks prior to their first medication.
  • According to the judgment of the researchers, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

China7 sites

  • Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

    Changsha, Hunan, 410005

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022

  • Shanghai Tenth Hospital, Tongji University

    Shanghai, Shanghai Municipality, 200032

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032

  • The Henan Cancer Hospital

    Zhengzhou, Henan, 450008

Other trials in China

About this study

Official title: Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors

TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such as advanced gastric/gastroesophageal junction cancer.

Being tested
TQB2210 Injection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TQB2210 InjectionDrug

    TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity. It inhibits tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor. Its binding is concentration dependent.

Study groups in NCT06929195
Study groupRoleWhat they receive
TQB2210 InjectionExperimentalDose escalation experiment: Intravenous infusion once of TQB2210 for injection every two weeks, 28 days as one treatment cycle. (1.0 mg/kg, 3.0 mg/kg, 8.0 mg/kg, 16.0 mg/kg, 24.0 mg/kg) Dose expansion experiment: Chose one or two appropriate dose groups in the dose escalation experiment to amplify.
Receives: Drug: TQB2210 Injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dose Limiting Toxicity (DLT)

    DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred within the first cycle(28 days) of treatment.

    Measured: During the first cycle. Each cycle is 28 days

  2. Maximum tolerated dose (MTD)

    MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.

    Measured: During the first cycle. Each cycle is 28 days

  3. Recommended Phase II Dose

    The recommended dosage for subsequent Phase II studies will be based on MTD (Maximum Tolerant Dose), pharmacokinetics, preliminary efficacy and safety comprehensively determined.

    Measured: During the first cycle. Each cycle is 28 days

  4. Objective Response Rate (ORR) (dose expansion phase)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria.

    Measured: Up to 2 years

Secondary outcomes (12)

  1. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs) evaluated by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Measured: Up to 2 years

  2. Objective Response Rate (ORR) (dose escalation phase)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria.

    Measured: Up to 2 years

  3. Disease control rate (DCR)

    Defined as the proportion of subjects with CR, PR, or Stable Disease (SD).

    Measured: Up to 2 years

  4. Duration of Response (DOR)

    Defined as the time from first documented response to documented disease progression.

    Measured: Up to 2 years

  5. Progress Free Survival (PFS)

    Defined as the time from the first dose of TQB2210 to the first occurrence of disease progression or death from any cause.

    Measured: Up to 2 years

  6. Overall Survival (OS)

    Overall survival refers to the time from the first treatment to death from any cause.

    Measured: Up to 2 years

  7. Pharmacokinetics: The area under the curve (AUC)

    The area under the curve (AUC) of serum concentration of TQB2210.

    Measured: 2 hours pre-dose, 0,2,6,24,48,72,120,168 hours after dose on cycle1 day1 and cycle3 day1; 2 hours pre-dose on cycle1 day15 and cycle3 day15, each cycle is 28 days.

  8. Pharmacokinetics:Peak concentration (Cmax)

    Maximum observed concentration (Cmax) of TQB2210 antibody.

    Measured: 2 hours pre-dose, 0,2,6,24,48,72,120,168 hours after dose on cycle1 day1 and cycle3 day1; 2 hours pre-dose on cycle1 day15 and cycle3 day15, each cycle is 28 days.

  9. Pharmacokinetics: T1/2

    Terminal half-life (T1/2)

    Measured: 2 hours pre-dose, 0,2,6,24,48,72,120,168 hours after dose on cycle1 day1 and cycle3 day1; 2 hours pre-dose on cycle1 day15 and cycle3 day15, each cycle is 28 days.

  10. Pharmacokinetics: Apparent Clearance (CL/F)

    Apparent Clearance： Apparent clearance refers to the rate of drug removal in the body, which reflects the degree of drug elimination in the body, as well as the bioavailability of the drug in the body

    Measured: 2 hours pre-dose, 0,2,6,24,48,72,120,168 hours after dose on cycle1 day1 and cycle3 day1; 2 hours pre-dose on cycle1 day15 and cycle3 day15, each cycle is 28 days.

  11. Pharmacokinetics: Vss/F

    When the drug distribution in plasma and tissue reaches equilibrium, the drug distribution in the body body according to the plasma drug concentration at this time is the required body fluid volume called apparent distribution volume.

    Measured: 2 hours pre-dose, 0,2,6,24,48,72,120,168 hours after dose on cycle1 day1 and cycle3 day1; 2 hours pre-dose on cycle1 day15 and cycle3 day15, each cycle is 28 days.

  12. Immunogenicity: The incidence of drug-resistant antibodies (ADA) and neutralizing antibodies (NAb)

    The incidence of drug-resistant antibodies (ADA) and neutralizing antibodies (NAb)

    Measured: Cycle1 Day1, Cycle2 Day1, Cycle6 Day1; Cycle12 Day1: pre-dose 120 minutes; At the end of treatment visit (EOT) 30 days after the end of the infusion. Each cycle is 28 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Apr 2025
  2. Study start16 May 2025
  3. Primary completion10 Apr 2026
  4. Study completion10 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06929195
Sponsor's protocol ID
TQB2210-I-01
Status last verified
Apr 2026
First submitted
8 Apr 2025
Last updated
14 Apr 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing TQB2210 Injection in people with Advanced Malignant Tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. at 7 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dose Limiting Toxicity (DLT) (time frame: During the first cycle. Each cycle is 28 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06929195.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in